Supercharged immune cells take on Hard-to-Treat myeloma
Disease control
Ongoing
This early-phase trial tests a new treatment for multiple myeloma that has returned or not responded to prior therapies, including BCMA-targeting treatments. The approach combines specially engineered natural killer (NK) cells (called TiNK) with an antibody drug (isatuximab) and …
Phase: PHASE1 • Sponsor: Elvira Umyarova • Aim: Disease control
Last updated May 07, 2026 18:43 UTC